A new paradigm of RNA-targeting therapeutics
Nucyrna’s oligonucleotide platform can target both Nuclear & Cytoplasmic RNA, enabling unique RNA-targeting capacities for addressing complex pathology.
Our technology has demonstrated a remarkable therapeutic index profile in CNS and we are focusing on neurodegenerative diseases.